

| Name | Vector | Origin | Description |
|--------------------------------------|-------------|-----------------------------------|---|
| AD8(+) | pBR322 | K. Strebel (NIAID, Bethesda, USA) | See reference (1). |
| AD8(-) | pBR322 | K. Strebel (NIAID, Bethesda, USA) | See reference (1). |
| AD8(U _{del2}) | pBR322 | K. Strebel (NIAID, Bethesda, USA) | See reference (2). |
| AD8(+) Δ Nef | pBR322 | this study | Nef-deficient AD8(+). Nef frame shift mutation introduced using the primers 5'-GGCCT ACTGT AAGGG AAAGA ATAGA CACGA GCTGA GC-3' and 5'-GCTCA GCTCG TGTCT ATTCT TTCCC TTACA GTAGG CC-3', and the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies, Wokingham, UK) according to the manufacturer's instructions. |
| AD8(-) Δ Nef | pBR322 | this study | Nef-deficient AD8(-). Nef frame shift mutation introduced as described for AD8(+) Δ Nef. |
| AD8(U _{del2}) Δ Nef | pBR322 | this study | Nef-deficient AD8(U _{del2}). Nef frame shift mutation introduced as described for AD8(+) Δ Nef. |
| VSVG | pMDG | G. Towers (UCL, London, UK) | - |
| AD8 Nef wild type | pcDNA3.1(+) | this study | The Nef open reading frame (ORF) was amplified from AD8(+) and inserted into pcDNA3.1 using BamH1 and EcoR1 restriction sites. |
| AD8 Vpu | pcDNA3.1(+) | this study | The Vpu open reading frame (ORF) was amplified from AD8(+) and inserted into pcDNA3.1 using BamH1 and EcoR1 restriction sites. |
| AD8 Env | pcDNA3.1(+) | this study | The Env open reading frame (ORF) was amplified from AD8(-) and inserted into pcDNA3.1 using BamH1 and EcoR1 restriction sites. |
| HIV-1 Rev | pBC12/CMV | G. Towers (UCL, London, UK) | - |
| AD8 Nef E160A_LL164/165AA | pcDNA3.1(+) | this study | The mutations LL164/165AA and E160A were consecutively introduced into AD8 Nef wild type using the primers 5'-CAATA AAGGA GAGAA CAACT GCGCG GCACA CCCTA TGAGC CAGCA TGGA-3' and 5'-TCCAT GCTGG CTCAT AGGGT GTGCC GCGCA GTTGT TCTCT CCTTT ATTG-3', and 5'-AGGCC AATAA AGGAG CGAAC AACTG CGCGG C-3' and 5'-GCCGC GCAGT TGTTT GCTCC TTTAT TGGCC T-3', respectively, and the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies) according to the manufacturer's instructions. |
| AD8 Nef DD174/175RA | pcDNA3.1(+) | this study | The mutation was introduced into AD8 Nef wild type using the primers 5'-CAACA CTTCT CTCTC CGTGG CACGC ATTCC ATGCT GGCTC ATA-3' and 5'-TATGA GCCAG CATGG AATGC GTGCC ACGGA GAGAG AAGTG TTG-3', and the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies) according to the manufacturer's instructions. |

| | | | |
|--|-------------|---|--|
| AD8 Nef E160A_LL164/165AA_ DD174/175RA | pcDNA3.1(+) | this study | The mutation DD174/175RA was introduced into AD8 Nef E160A_LL164/165A using the primers listed above and the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies) according to the manufacturer's instructions. |
| AD8 Nef G2A | pcDNA3.1(+) | this study | The mutation was introduced into AD8 Nef wild type using the primers 5'-CTCGG ATCCA AGATG GCTGG CAAGT GGTCA AAA-3' and 5'-TTTTG ACCAC TTGCC AGCCA TCTTG GATCC GAG-3', and the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies) according to the manufacturer's instructions. |
| NL4.3 Nef | pcDNA3.1(+) | this study | The Nef open reading frame (ORF) was amplified from pNL4.3 (provided by C. Jolly, UCL, London, UK) and inserted into pcDNA3.1 using BamH1 and EcoR1 restriction sites. |
| AD8-NL4.3 Nef | pcDNA3.1(+) | this study | The N-terminal AD8 Nef domain was excised from AD8 Nef wild type using BamH1 and Bgl2 and ligated into NL4.3 Nef digested with the same restriction enzymes. |
| NL4.3-AD8 Nef | pcDNA3.1(+) | this study | The N-terminal NL4.3 Nef domain was excised from NL4.3 Nef using BamH1 and Bgl2, and ligated into AD8 Nef wild type digested with the same restriction enzymes. |
| AD8 Nef IRES GFP | pCG | this study | The ORF was inserted into pCG using Xba1 and Mlu1 restriction sites. |
| NL4.3 Nef IRES GFP | pCG | modified in this study (originally obtained from F. Kirchhoff, University of Ulm, Germany) | The ORF was inserted into pCG using Xba1 and Mlu1 restriction sites. |
| JR-CSF Nef IRES GFP | pCG | F. Kirchhoff (University of Ulm, Germany) | - |
| SF2 Nef IRES GFP | pCG | F. Kirchhoff (University of Ulm, Germany) | - |
| CH077 Nef IRES GFP | pCG | F. Kirchhoff (University of Ulm, Germany) | - |
| CH198 Nef IRES GFP | pCG | F. Kirchhoff (University of Ulm, Germany) | - |
| 2693BA Nef IRES GFP | pCG | F. Kirchhoff (University of Ulm, Germany) | - |
| OMRCA Nef IRES GFP | pCG | modified in this study (originally obtained from F. Kirchhoff, University of Ulm, Germany) | The ORF was inserted into pCG using Xba1 and Mlu1 restriction sites. |
| 13127K2 Nef IRES GFP | pCG | F. Kirchhoff (University of Ulm, Germany) | - |
| RBF168 Nef IRES GFP | pCG | F. Kirchhoff (University of Ulm, Germany) | - |
| 7312 Nef IRES GFP | pCG | modified in this study (originally obtained from | The ORF was inserted into pCG using Xba1 and Mlu1 restriction sites. |

| | | | |
|-------------------------|-----|---|---|
| | | F. Kirchhoff, University of Ulm, Germany) | |
| NL4.3 Nef_stop IRES GFP | pCG | F. Kirchhoff (University of Ulm, Germany) | - |

1. **Theodore TS, Englund G, Buckler-White A, Buckler CE, Martin MA, Peden KW.** 1996. Construction and characterization of a stable full-length macrophage-tropic HIV type 1 molecular clone that directs the production of high titers of progeny virions. *AIDS Res Hum Retroviruses* **12**:191–194.
2. **Schubert U, Clouse KA, Strebel K.** 1995. Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes. *J Virol* **69**:7699–7711.

